@article{779b46f83e874648aed667baf8bffeba,
title = "PSMA-targeted [ 18 F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework",
abstract = "We present the case of a man with oligometastatic prostate cancer who underwent a PSMA-targeted 18F-DCFPyL PET/CT scan in order to illustrate how the PSMA-RADS grading sytem can be successfully used to support clinical decision-making and treatment planning. Notably, the presented patient was found to have an equivocal bone lesion (PSMA-RADS-3B) which was further worked up with a tumor protocol MRI and found to be definitively benign (PSMA-RADS-1B) and thus removed from the oligometastatic treatment plan. Remaining avid lesions were incorporated into the treatment plan or deferred for later work-up or monitoring, as indicated within the PSMA-RADS framework.",
keywords = "DCFPyL, Oligometastatic, PSMA, Prostate cancer",
author = "Reyes, {Diane K.} and Shadpour Demehri and Werner, {Rudolf A.} and Pomper, {Martin G.} and Gorin, {Michael A.} and Rowe, {Steven P.} and Pienta, {Kenneth J.}",
note = "Funding Information: We gratefully acknowledge funding from the Prostate Cancer Foundation Young Investigator Award, Progenics Pharmaceuticals, Inc., and the National Institutes of Health grants CA134675, CA183031, CA184228, and EB024495. This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 701983. Funding Information: M.G.P. is a co-inventor on a U.S. patent covering 18 F-DCFPyL and as such is entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. M.A.G. has served as a consultant to Progenics Pharmaceuticals, the licensee of 18 F-DCFPyL. S.P.R., M.A.G., K.J.P., and M.G.P. have all received research funding from Progenics Pharmaceuticals. No other authors have declared any relevant conflicts of interest. Publisher Copyright: {\textcopyright} 2019",
year = "2019",
month = mar,
doi = "10.1016/j.eucr.2019.01.007",
language = "English (US)",
volume = "23",
pages = "72--74",
journal = "Urology Case Reports",
issn = "2214-4420",
publisher = "Elsevier Saunders",
}